---
title: "Cartesian Therapeutics, Inc. (RNAC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RNAC.US.md"
symbol: "RNAC.US"
name: "Cartesian Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-06-13T16:25:53.531Z"
locales:
  - [en](https://longbridge.com/en/quote/RNAC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RNAC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RNAC.US.md)
---

# Cartesian Therapeutics, Inc. (RNAC.US)

## Company Overview

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.cartesiantherapeutics.com](https://www.cartesiantherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:14.000Z

**Overall: E (0.82)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 367 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -94.81% |  |
| Net Profit YoY | -256.96% |  |
| P/B Ratio | -1.89 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 279418198.14 |  |
| Revenue | 1775000.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 178.66% | A |
| Profit Margin | -8550.65% | E |
| Gross Margin | -24852.56% | E |
| Revenue YoY | -94.81% | E |
| Net Profit YoY | -256.96% | E |
| Total Assets YoY | -29.51% | E |
| Net Assets YoY | -579.78% | E |
| Cash Flow Margin | 48.08% | C |
| OCF YoY | -94.81% | E |
| Turnover | 0.01 | E |
| Gearing Ratio | 151.36% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Cartesian Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-94.81%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-256.96%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-1.89",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "279418198.14",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1775000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "178.66%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-8550.65%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-24852.56%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-94.81%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-256.96%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-29.51%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-579.78%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "48.08%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-94.81%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "151.36%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.84 | 237/390 | - | - | - |
| PB | -1.89 | 497/390 | - | - | - |
| PS (TTM) | 157.42 | 266/390 | 232.14 | 161.84 | 59.33 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-11T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 88% |
| Overweight | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.51 |
| Highest Target | 44.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RNAC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RNAC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RNAC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RNAC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**